Nanoform Finland Oyj Annual cash flow by MarketWatch. View NANOFS net cash flow, operating cash flow, operating expenses and cash dividends. Skip to main content Main Menu ...

The agreement specifies that Nanoform will provide non-GMP nanomaterial to Takeda for in-vivo studies, the first results of which should be delivered by early 2025. Nanoform, based in Helsinki, ...

(MENAFN- PR Newswire) HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical ...

HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV ...

STARMAP will accelerate the selection of AZ’s best molecule candidates STARMAP will accelerate the selection of AZ’s best molecule candidates AstraZeneca (AZ) has been granted a global online licence ...

Helsinki, Finland – Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has partnered with Pharmanovia, a fast-growing specialty pharma business with a ...

Christian Jones, CCO [email protected] / +44 7804 474771 For investor relations queries, please contact: Henri von Haartman , Director of Investor Relations [email protected] / +46 7686 ...

HELSINKI, Sept. 9, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc ("Herantis"), focusing on disease modifying ...

Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for ...